2017
Gender differences in the real-world effectiveness of smoking cessation medications: Findings from the 2010–2011 Tobacco Use Supplement to the Current Population Survey
Smith PH, Zhang J, Weinberger AH, Mazure CM, McKee SA. Gender differences in the real-world effectiveness of smoking cessation medications: Findings from the 2010–2011 Tobacco Use Supplement to the Current Population Survey. Drug And Alcohol Dependence 2017, 178: 485-491. PMID: 28715776, PMCID: PMC6779031, DOI: 10.1016/j.drugalcdep.2017.05.046.Peer-Reviewed Original ResearchConceptsTransdermal nicotine patchUnassisted quit attemptsClinical trial dataTobacco Use SupplementQuit attemptsTrial dataClinical trial findingsReal-world effectivenessSample of smokersGender differencesRelevant gender differencesCessation optionsCessation medicationsCessation pharmacotherapyNicotine patchMedication interactionsSmoking cessationPotential confoundersTrial findingsVareniclineComparative effectivenessPropensity scoreCross-sectional dataWomenMedications
2014
Consideration of Sex in Clinical Trials of Transdermal Nicotine Patch: A Systematic Review
Weinberger AH, Smith PH, Kaufman M, McKee SA. Consideration of Sex in Clinical Trials of Transdermal Nicotine Patch: A Systematic Review. Experimental And Clinical Psychopharmacology 2014, 22: 373-383. PMID: 25133506, PMCID: PMC4180800, DOI: 10.1037/a0037692.Peer-Reviewed Original ResearchConceptsTransdermal nicotine patchNicotine patchCessation outcomesClinical trialsSmoking cessationSmoking cessation treatmentMenstrual cycle phaseCessation treatmentSex-related variablesInclusion criteriaMEDLINE searchSmoking treatmentSide effectsBetter outcomesTreatment efficacyConsideration of sexSystematic reviewPotential articlesInclusion of sexSkin irritationMore womenTrialsOutcomesSexWomen
2008
Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation
O'Malley SS, Krishnan-Sarin S, McKee SA, Leeman RF, Cooney NL, Meandzija B, Wu R, Makuch RW. Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation. The International Journal Of Neuropsychopharmacology 2008, 12: 589-597. PMID: 18796184, PMCID: PMC3094855, DOI: 10.1017/s146114570800936x.Peer-Reviewed Original ResearchConceptsHazardous drinkingSmoking cessationFavorable side effect profileDose-ranging clinical trialAlcohol useEffects of NTXPlacebo-controlled trialDose-ranging trialSide effect profileTransdermal nicotine patchOpiate antagonist naltrexoneDose-dependent reductionComponent of treatmentHazardous alcohol useOral NTXSecondary outcomesNicotine patchPrimary outcomeAntagonist naltrexoneCombination therapyClinical trialsBaseline predictorsOral preparationsHazardous drinkersNTX